Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ghez

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Ejhaem|March 20, 2025
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World AnalysisThomas Hueso, Grégory Lazarian, Paul Chauvet, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisisDavid Ghez, Jean-Baptiste Micol, Florence Pasquier, et al.
European Journal of Haematology|December 16, 2019
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II resultJean-Marie Michot, Maxime Annereau, Alina Danu, et al.
Blood Advances|October 7, 2020
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patientsKamel Laribi, Alix Baugier de Materre, Mohamad Sobh, et al.
Haematologica|March 24, 2022
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphomaCyril Quivoron, Anthony Tarabay, Jean-Marie Michot, et al.
Leukemia & Lymphoma|November 23, 2017
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experienceKhalil Saleh, Alina Danu, Serge Koscielny, et al.
Leukemia & Lymphoma|January 26, 2011
Clinical and biological features of t(4;14) multiple myeloma: a prospective studyLionel Karlin, Jean Soulier, Olivia Chandesris, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphomaJean-Marie Michot, Alice Buet-Elfassy, Maxime Annereau, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 10, 2015
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal typeJean-Marie Michot, Renaud Mazeron, Alina Danu, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Ejhaem|March 20, 2025
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World AnalysisThomas Hueso, Grégory Lazarian, Paul Chauvet, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisisDavid Ghez, Jean-Baptiste Micol, Florence Pasquier, et al.
European Journal of Haematology|December 16, 2019
High-dose cyclophosphamide for hard-to-treat patients with relapsed or refractory B-cell non-Hodgkin's lymphoma, a phase II resultJean-Marie Michot, Maxime Annereau, Alina Danu, et al.
Blood Advances|October 7, 2020
Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patientsKamel Laribi, Alix Baugier de Materre, Mohamad Sobh, et al.
Haematologica|March 24, 2022
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphomaCyril Quivoron, Anthony Tarabay, Jean-Marie Michot, et al.
Leukemia & Lymphoma|November 23, 2017
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experienceKhalil Saleh, Alina Danu, Serge Koscielny, et al.
Leukemia & Lymphoma|January 26, 2011
Clinical and biological features of t(4;14) multiple myeloma: a prospective studyLionel Karlin, Jean Soulier, Olivia Chandesris, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphomaJean-Marie Michot, Alice Buet-Elfassy, Maxime Annereau, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
European Journal of Cancer (Oxford, England : 1990)|August 10, 2015
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal typeJean-Marie Michot, Renaud Mazeron, Alina Danu, et al.
Pageof 8